Regulatory News: Onxeo S.A. (Euronext Growth Paris: ALONX), hereafter "Onxeo" or the "Company", a clinical stage biotechnology company specializing in the development of innovative drugs targeting
OX425 is a novel DDR Decoy Agonist which also mediates multiple immunostimulatory effects, making it a promising candidate for combination with immunotherapy, especially in "cold" tumors Late-stage
> Refocusing R&D efforts as well as accelerating preclinical and clinical programs globally> Cash position of €26.9 million as of June 30, 2022> Financial visibility assured until Q2 2023PARIS (BUSINESS WIRE) Regulatory News:Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North Copenhagen1: ONXEO), hereafte.
Onxeo Reports its Half-Year 2022 Financial Results and Provides an Update on its Activities streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
> Refocusing R&D efforts as well as accelerating preclinical and clinical programs globally > Cash position of €26.9 million as of June 30, 2022 > Financial visibility assured until Q2 2023 Regulatory